# GSTA1 deficiency drives neuroendocrine differentiation via TNFRSF13B/c-FOS/CHGA axis in prostate cancer

**Authors:** Jiajun Qian, Yang Luo, Yao Fu, Wenli Diao, Qiubo Ding, Wei Chen, Xuefeng Qiu, Hongqian Guo

PMC · DOI: 10.7150/ijbs.120497 · International Journal of Biological Sciences · 2026-01-14

## TL;DR

This study finds that low GSTA1 levels in prostate cancer cells increase neuroendocrine traits through a chain of molecular events involving ROS, TNFRSF13B, and CHGA.

## Contribution

The study identifies a novel GSTA1-driven pathway linking oxidative stress to neuroendocrine differentiation in prostate cancer.

## Key findings

- GSTA1 deficiency increases reactive oxygen species and activates TNFRSF13B in prostate cancer cells.
- Reduced GSTA1 promotes neuroendocrine differentiation via the TNFRSF13B/c-FOS/CHGA axis.
- Lower GSTA1 levels are observed in patients with neuroendocrine prostate cancer.

## Abstract

Rationale: Androgen deprivation therapy (ADT) is the cornerstone of prostate cancer (PCa) treatment. Prolonged ADT inevitably increases the risk of neuroendocrine differentiation, which leads to the development of hormone-refractory subtypes. In this study, we explored the molecular mechanisms underlying the neuroendocrine differentiation of PCa cells under ADT.

Methods: We performed digital spatial profiling (DSP) sequencing using tissue microarrays from five patients with PCa who underwent neoadjuvant therapy before radical prostatectomy at the Nanjing Drum Tower Hospital.

Results: Glutathione S-transferase alpha 1 (GSTA1) was identified as a driver of neuroendocrine differentiation in PCa cells using DSP sequencing of tissue microarrays prepared from clinical samples. Following enzalutamide (ENZ) treatment, GSTA1 expression is inhibited. Decreased GSTA1 levels have also been reported in patients with neuroendocrine PCa (NEPC). GSTA1 knockdown leads to increased intracellular reactive oxygen species (ROS), which can activate the inflammatory gene, tumor necrosis factor receptor superfamily member 13B (TNFRSF13B). TNFRSF13B induces c-Fos expression, forming a transcriptional complex with c-Jun, thereby regulating chromogranin A (CHGA) and promoting the neuroendocrine phenotype.

Conclusion: Our study suggested that GSTA1 deficiency leads to elevated ROS levels and activation of TNFRSF13B and c-FOS, which subsequently transcriptionally regulate CHGA and ultimately drive neuroendocrine differentiation in PCa.

## Linked entities

- **Genes:** GSTA1 (glutathione S-transferase alpha 1) [NCBI Gene 2938], TNFRSF13B (TNF receptor superfamily member 13B) [NCBI Gene 23495], FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353], CHGA (chromogranin A) [NCBI Gene 1113]
- **Chemicals:** enzalutamide (PubChem CID 15951529)
- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Genes:** JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, TNFRSF13B (TNF receptor superfamily member 13B) [NCBI Gene 23495] {aka CD267, CVID, CVID2, IGAD2, RYZN, TACI}, GSTA1 (glutathione S-transferase alpha 1) [NCBI Gene 2938] {aka GST-epsilon, GST2, GSTA1-1, GTH1}, CHGA (chromogranin A) [NCBI Gene 1113] {aka CGA, PHE5, PHES}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}
- **Diseases:** inflammatory (MESH:D007249), NEPC (MESH:D011471)
- **Chemicals:** ENZ (MESH:C540278), ROS (MESH:D017382)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12839132/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12839132/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC12839132/full.md

---
Source: https://tomesphere.com/paper/PMC12839132